The oral drug for covid-19 virus developed by yanyeyi pharmaceutical company, a Japanese pharmaceutical company headquartered in Osaka Prefecture, has officially submitted an application for clinical treatment approval to the Ministry of health, labor and welfare of Japan on February 25. The news shows that the efficacy of this Japanese covid-19 oral drug “ensitrelvir (s-217622)” exceeds several oral drugs produced in the United States, and the final cure rate can reach 100%.
In view of the severity of the current overseas epidemic, “covid-19 vaccine + specific drug” is considered to be the best means of epidemic prevention and control. Analysts pointed out that according to the announcement and annual report previously released by Pfizer, the price of a single course of paxlovid is $529. It is expected that the revenue of covid-19 oral medicine will reach $22 billion in covid-19 treatment products in 2022. Covid-19 oral medicine, as the last puzzle in covid-19 treatment industry chain, has broad market prospects.
According to the theme database of financial Associated Press, among the relevant listed companies:
Pku Healthcare Corp.Ltd(000788) 2020 Ping An Insurance (Group) Company Of China Ltd(601318) invested 2.1 billion yuan to become an important strategic shareholder of yanyeyi pharmaceutical, Pku Healthcare Corp.Ltd(000788) is currently the only listing platform of Ping An health, with a national sales network and a perfect API production line
Changjiangrunfa Health Industry Co.Ltd(002435) subsidiary has a good cooperative relationship with yanyeyi pharmaceutical company for many years. Yanyeyi was an important shareholder of Shanghai Yiwei Industrial Co., Ltd. The company is cooperating closely with yanyeyi Changao Pharmaceutical Technology Group Co., Ltd.
